Drug Profile
Research programme: oral therapeutics - Activus Pharma/CEOLIA Pharma
Latest Information Update: 19 Jul 2019
Price :
$50
*
At a glance
- Originator Activus Pharma; CEOLIA Pharma
- Developer Activus Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Japan (PO)
- 25 Jan 2012 Early research in Undefined indication in Japan (PO)